A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer

Table 1 Brief description of the SNPs analyzed in this study

Gen	SNP ID	AA Change	SNPs effect	Genotype associated to toxicity	Allelic frequency American population (n)^a	Toxicity
GSTP1	rs1695, A > G	I105V	Protein alteration	AA and AG	Allele A: 0.52	↑ risk of hematological toxicity
ERCC2	rs13181, T > G	K751Q	Protein alteration	GG and GT	Allele G: 0.21	↑ risk of hematological toxicity
TP53	rs1042522, C > G	P72R	Protein alteration	CG and GG	Allele G: 0.32	↑ risk of hematological toxicity
UMPS	rs1801019, G > C	G213A	Protein alteration	CC	Allele C: 0.26	↑ risk of gastrointestinal toxicity
SHMT1	rs1979277, G > A	L474F	Protein alteration	AA	Allele A: 0.27	↑ risk of toxicity
MTHFR	rs1801131, T > G	E429A	Protein alteration	TT	Allele T: 0.15	↑ risk of toxicity
ABCC2	rs717620, C > T	–	Change in 5`-UTR	TT	Allele T: 0.17	↑ risk of neurotoxicity
ERCC1	rs11615, A > G	N118=	Synonymous change	AA	Allele A: 0.39	↑ risk of hematological toxicity
DPYD	rs2297595, T > C	M166V	Protein alteration	CC and CT	Allele C: 0.06	↑ risk of severe toxicity
DPYD	rs1801159, T > C	I543V	Protein alteration	CC and CT	Allele C: 0.27	↑ risk of severe toxicity
DPYD	rs1801265, A > G	C29R	Protein alteration	GG and AG	Allele G: 0.22	↑ risk of severe toxicity

^a Frequencies of genotypes associated to toxicity in American population according 1000-G project

ISSN: 1471-2407